Ohio State’s Nisonger Center is accepting children ages 4-12 for a 14-week study of mecamylamine in Autism, including Pervasive Development Disorder – Not Otherwise Specified (PDD-NOS). Evaluation and treatment are free. Some reimbursement for travel and time provided. There is a chance of placebo, but everyone gets to try active medication. Risks and benefits explained prior to participation. For more information without obligation, call (614) 292-3698 or visit http://psychmed.osu.edu.